glutathione trapping reactive metabolites 14 Formation of a metabolite by conjugation Site of Reactivity Models Predict
Description
Multiple Concentrations Available: Offered in concentrations of 1% and 2% to allow for tailored dosing
The following outline is based on clinical practices and published usage patterns among healthcare providers: Initial phase: 2.0-2.5 mg administered subcutaneously or intramuscularly every other day
The valine backbones of GRXC2 and ROXY9 cannot be perfectly superimposed due to the different positioning of the loop in the two proteins
PloS One 11, e0167295
